We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » J&J’s Blockbuster Diabetes Drug Invokana Receives Boxed Warning Over Amputation Risk
J&J’s Blockbuster Diabetes Drug Invokana Receives Boxed Warning Over Amputation Risk
The FDA has issued a boxed warning for Johnson & Johnson’s Invokana (canagliflozin) treatment for type 2 diabetes, describing a doubled risk of leg and foot amputations compared to placebo. In 2016, Invokana brought in more than $1.4 billion in sales.